[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-senomune-0257-fact-check-zh":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"read":15,"author":16,"image":17,"body":18,"_type":1368,"_id":1369,"_source":1370,"_file":1371,"_stem":1372,"_extension":1373},"\u002Fblog\u002Fzh\u002Fsenomune-0257-fact-check","zh",false,"","SenoMune-0257 事实核查：真是能“治愈癌症”的肽吗？","下面是一般性的科普内容，不是医疗建议，也不是鼓励你去弄点什么来用。SenoMune-0257 在任何地方都买不到，也从没在任何一个人身上试过。它没有所谓的用量，我们这里也不给任何用量。","事实核查","tabler:zoom-question","#F2A93B","2026-10-26","2026年10月","12 分钟","myPeptides Team","\u002Fassets\u002Fsenomune_hero.png",{"type":19,"children":20,"toc":1353},"root",[21,28,34,39,44,49,54,70,75,80,94,99,105,119,124,129,134,140,233,238,243,249,272,295,309,332,355,387,393,407,412,434,439,462,467,472,486,500,505,510,529,534,546,551,556,561,575,589,594,599,605,610,793,798,803,817,822,828,842,864,870,914,919,924,929,950,955],{"type":22,"tag":23,"props":24,"children":25},"element","p",{},[26],{"type":27,"value":9},"text",{"type":22,"tag":29,"props":30,"children":32},"h2",{"id":31},"先说结论",[33],{"type":27,"value":31},{"type":22,"tag":23,"props":35,"children":36},{},[37],{"type":27,"value":38},"2026 年 10 月 24 日，X 上的一条帖子把 SenoMune-0257 称作“cancer curing peptide”（能治愈癌症的肽），还说年底前就会开始人体试验。这条帖子的依据，是美国公司 Immorta Bio 发布的一份新闻稿。稿子介绍的是一种由九个氨基酸组成的肽，用途是帮助免疫系统清除衰老的细胞。里面没有任何数据，也没说这种肽打算用来治什么病。",{"type":22,"tag":23,"props":40,"children":41},{},[42],{"type":27,"value":43},"最先把它和癌症联系在一起的，其实是公司自己：前一天，公司的首席科学官已经把 SenoMune-0257 叫作“cancer immunotherapy”（癌症免疫疗法）。到了那条帖子里，又变成了“cancer curing”（治愈癌症），而这个说法在任何来源里都找不到依据。",{"type":22,"tag":23,"props":45,"children":46},{},[47],{"type":27,"value":48},"我们的结论是：这条帖子的说法，远远超出了来源能支撑的范围。关于 SenoMune-0257，至今没有任何正式发表的内容，没有登记任何人体试验，序列也没有公开。现有的几篇论文讲的是另一款叫 SenoVax 的产品，做的是小鼠实验和细胞培养，而且都出自这家公司自己。",{"type":22,"tag":29,"props":50,"children":52},{"id":51},"那条疯传的帖子",[53],{"type":27,"value":51},{"type":22,"tag":23,"props":55,"children":56},{},[57,59,68],{"type":27,"value":58},"帖子来自账号 ",{"type":22,"tag":60,"props":61,"children":65},"a",{"href":62,"rel":63},"https:\u002F\u002Fx.com\u002FItsPeptime\u002Fstatus\u002F2114006612188991733",[64],"nofollow",[66],{"type":27,"value":67},"@ItsPeptime",{"type":27,"value":69},"，截至 10 月 26 日，浏览量约 19 万次，点赞 5,100 次，转发 457 次。原文写道：“BREAKING: Cancer Curing peptide Senomune-0257 just completed pre-clinical studies successfully, promising human trials by end of year.”（突发：可治愈癌症的肽 Senomune-0257 刚刚顺利完成临床前研究，有望在年底前开始人体试验。）",{"type":22,"tag":23,"props":71,"children":72},{},[73],{"type":27,"value":74},"帖子接着又说：“This new peptide mimics cells which attack cancers, amplifying the bodies natural immune response!”（这种新肽能模仿攻击癌症的细胞，放大身体天然的免疫反应！）",{"type":22,"tag":23,"props":76,"children":77},{},[78],{"type":27,"value":79},"这个账号是 2026 年 1 月注册的。它在简介里引导读者到自家网站购买“99% pure USA peptides”（纯度 99% 的美国产肽），而那个网站自称“The American Peptide Vendor”（美国肽供应商）。",{"type":22,"tag":23,"props":81,"children":82},{},[83,85,92],{"type":27,"value":84},"就在这条帖子发出前大约 22 小时，Immorta 的首席科学官 Thomas Ichim ",{"type":22,"tag":60,"props":86,"children":89},{"href":87,"rel":88},"https:\u002F\u002Fx.com\u002Fexosome\u002Fstatus\u002F2113677196380508376",[64],[90],{"type":27,"value":91},"在 X 上写道",{"type":27,"value":93},"，公司“discovered the first cancer immunotherapy that fights aging”（发现了第一种能对抗衰老的癌症免疫疗法）。截至 10 月 26 日，他这条帖子的浏览量约 15.3 万次。",{"type":22,"tag":23,"props":95,"children":96},{},[97],{"type":27,"value":98},"所以，癌症这个说法并不是那条疯传的帖子凭空编出来的，但它把话又往前推了一步。“对抗衰老的癌症免疫疗法”到了它嘴里，成了“治愈癌症”。在我们能找到的所有公司表述里，没有一处用过这个词。",{"type":22,"tag":29,"props":100,"children":102},{"id":101},"immorta-bio-到底宣布了什么",[103],{"type":27,"value":104},"Immorta Bio 到底宣布了什么",{"type":22,"tag":23,"props":106,"children":107},{},[108,110,117],{"type":27,"value":109},"Immorta 在 ",{"type":22,"tag":60,"props":111,"children":114},{"href":112,"rel":113},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-pioneers-ai-designed-senolytic-immunotherapy-targeting-diseases-of-aging-302905700.html",[64],[115],{"type":27,"value":116},"2026 年 10 月 12 日的新闻稿",{"type":27,"value":118},"中宣布，“an AI-designed peptide immunotherapy”（一种由 AI 设计的肽类免疫疗法）已经走完临床前阶段，原话是“completion of its planned preclinical studies”（计划中的临床前研究已经完成）。所谓临床前，指的是在人身上做任何试验之前的实验室工作。新闻稿对产品的描述是“a synthetic nine-amino-acid peptide designed to stimulate targeted immune responses against senescent cells”（一种人工合成的九氨基酸肽，用来激发针对衰老细胞的定向免疫反应）。",{"type":22,"tag":23,"props":120,"children":121},{},[122],{"type":27,"value":123},"按公司的说法，这种肽能激活一类专门杀伤其他细胞的免疫细胞（细胞毒性 T 细胞）。据称，这些 T 细胞能清除衰老细胞，“while sparing healthy cells under the conditions tested”（在测试条件下不伤及健康细胞）。新闻稿说这款产品“potentially universal, off-the-shelf”（有望通用、现成可用），并预计 2026 年底前进行“initial human evaluation”（首次人体评估）。",{"type":22,"tag":23,"props":125,"children":126},{},[127],{"type":27,"value":128},"新闻稿没有给出氨基酸序列，没说靶蛋白是什么，也没交代这种肽和哪种组织型相匹配（也就是它的 HLA 限制性，下文会解释）。稿子里没有任何实验数字，也没提是否做过动物实验。",{"type":22,"tag":23,"props":130,"children":131},{},[132],{"type":27,"value":133},"新闻稿也没有提到试验地点和受试者人数，没说向美国食品药品监督管理局（FDA）递交过任何申请。稿子自带的免责声明写明，SenoMune-0257“remains investigational, and its safety and efficacy have not been established in humans.”（仍处于研究阶段，在人体中的安全性和有效性尚未得到证实。）",{"type":22,"tag":29,"props":135,"children":137},{"id":136},"逐句对照帖子怎么说来源怎么说",[138],{"type":27,"value":139},"逐句对照：帖子怎么说，来源怎么说",{"type":22,"tag":141,"props":142,"children":143},"table",{},[144,163],{"type":22,"tag":145,"props":146,"children":147},"thead",{},[148],{"type":22,"tag":149,"props":150,"children":151},"tr",{},[152,158],{"type":22,"tag":153,"props":154,"children":155},"th",{},[156],{"type":27,"value":157},"帖子的说法",{"type":22,"tag":153,"props":159,"children":160},{},[161],{"type":27,"value":162},"来源里的说法",{"type":22,"tag":164,"props":165,"children":166},"tbody",{},[167,181,194,207,220],{"type":22,"tag":149,"props":168,"children":169},{},[170,176],{"type":22,"tag":171,"props":172,"children":173},"td",{},[174],{"type":27,"value":175},"“Cancer Curing”（治愈癌症）",{"type":22,"tag":171,"props":177,"children":178},{},[179],{"type":27,"value":180},"没有任何来源这么说。Ichim 自己的帖子称它为“cancer immunotherapy that fights aging”（对抗衰老的癌症免疫疗法），这是在描述产品，不是在讲结果。新闻稿没有给 SenoMune-0257 指明任何癌症适应证，也没有报告任何癌症数据。",{"type":22,"tag":149,"props":182,"children":183},{},[184,189],{"type":22,"tag":171,"props":185,"children":186},{},[187],{"type":27,"value":188},"“completed pre-clinical studies successfully”（顺利完成临床前研究）",{"type":22,"tag":171,"props":190,"children":191},{},[192],{"type":27,"value":193},"新闻稿写的是“completion of its planned preclinical studies”（计划中的临床前研究已经完成）。它没有说“successfully”（顺利、成功），也没有拿出任何结果。",{"type":22,"tag":149,"props":195,"children":196},{},[197,202],{"type":22,"tag":171,"props":198,"children":199},{},[200],{"type":27,"value":201},"“promising human trials by end of year”（有望年底前开始人体试验）",{"type":22,"tag":171,"props":203,"children":204},{},[205],{"type":27,"value":206},"新闻稿写的是“initial human evaluation anticipated before year-end”（预计年底前进行首次人体评估）。目前没有登记任何试验。",{"type":22,"tag":149,"props":208,"children":209},{},[210,215],{"type":22,"tag":171,"props":211,"children":212},{},[213],{"type":27,"value":214},"“mimics cells which attack cancers”（模仿攻击癌症的细胞）",{"type":22,"tag":171,"props":216,"children":217},{},[218],{"type":27,"value":219},"没有任何来源这么说。按照新闻稿，这种肽的作用是激发 T 细胞去对付衰老细胞，它并不模仿任何细胞。",{"type":22,"tag":149,"props":221,"children":222},{},[223,228],{"type":22,"tag":171,"props":224,"children":225},{},[226],{"type":27,"value":227},"“amplifying the bodies natural immune response”（放大身体天然的免疫反应）",{"type":22,"tag":171,"props":229,"children":230},{},[231],{"type":27,"value":232},"来源里找不到这种说法。新闻稿用的措辞是“restore the immune system's ability”（恢复免疫系统的能力）。",{"type":22,"tag":23,"props":234,"children":235},{},[236],{"type":27,"value":237},"其中有两条最要紧。先说“治愈癌症”：关于这种肽，没有发表过任何癌症数据，无论是来自病人、小鼠，还是培养皿里的细胞。公司说做了实验室研究，却没拿出一个数字。这家公司发表过的癌症结果，来自它更早的产品 SenoVax，而且是在小鼠身上做的。",{"type":22,"tag":23,"props":239,"children":240},{},[241],{"type":27,"value":242},"“模仿细胞”则是把机制说错了。照公司的描述，这种肽只是一小段蛋白质，作用是告诉 T 细胞该攻击谁，并不是什么细胞的仿制品。",{"type":22,"tag":29,"props":244,"children":246},{"id":245},"衰老细胞是什么研究者为什么想清除它们",[247],{"type":27,"value":248},"衰老细胞是什么，研究者为什么想清除它们",{"type":22,"tag":23,"props":250,"children":251},{},[252,254,261,263,270],{"type":27,"value":253},"身体里的大多数细胞会分裂一段时间，然后停下来（",{"type":22,"tag":60,"props":255,"children":258},{"href":256,"rel":257},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F13905658\u002F",[64],[259],{"type":27,"value":260},"Hayflick 和 Moorhead，1961",{"type":27,"value":262},"）。有些细胞永久停止了分裂，却又不死，这类细胞叫作衰老细胞，通俗文章里常叫它们“僵尸细胞”。它们会释放炎症信号（",{"type":22,"tag":60,"props":264,"children":267},{"href":265,"rel":266},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F19053174\u002F",[64],[268],{"type":27,"value":269},"Coppé 等，2008",{"type":27,"value":271},"），而且会随着年龄增长越积越多。",{"type":22,"tag":23,"props":273,"children":274},{},[275,277,284,286,293],{"type":27,"value":276},"在小鼠身上，清除这些细胞确实有好处。2011 年，",{"type":22,"tag":60,"props":278,"children":281},{"href":279,"rel":280},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F22048312\u002F",[64],[282],{"type":27,"value":283},"Baker 和同事",{"type":27,"value":285},"在一种衰老得特别快的小鼠身上，用基因手段清除了衰老细胞，与年龄相关的变化随之推迟出现。2016 年，同一个团队又",{"type":22,"tag":60,"props":287,"children":290},{"href":288,"rel":289},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26840489\u002F",[64],[291],{"type":27,"value":292},"在普通小鼠身上做了同样的实验",{"type":27,"value":294},"，从小鼠一岁起开始清除。结果它们的中位寿命（也就是一半小鼠死亡时的年龄）延长了，肿瘤也出现得更晚。",{"type":22,"tag":23,"props":296,"children":297},{},[298,300,307],{"type":27,"value":299},"2018 年，",{"type":22,"tag":60,"props":301,"children":304},{"href":302,"rel":303},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F29988130\u002F",[64],[305],{"type":27,"value":306},"Xu 和同事",{"type":27,"value":308},"给老年小鼠用了两种药：达沙替尼（dasatinib）和槲皮素（quercetin）。从开始用药算起，小鼠的存活时间延长了 36%。",{"type":22,"tag":23,"props":310,"children":311},{},[312,314,321,323,330],{"type":27,"value":313},"到了人身上，结果就没那么清楚了。一项",{"type":22,"tag":60,"props":315,"children":318},{"href":316,"rel":317},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F30616998\u002F",[64],[319],{"type":27,"value":320},"先导研究",{"type":27,"value":322},"让 14 名肺病患者（特发性肺纤维化）服用这两种药，他们的体能有所改善，肺功能却没有变好。这项研究没有设对照组。2020 年 8 月，UNITY Biotechnology ",{"type":22,"tag":60,"props":324,"children":327},{"href":325,"rel":326},"https:\u002F\u002Fwww.sec.gov\u002FArchives\u002Fedgar\u002Fdata\u002F1463361\u002F000119312520222493\u002Fd28349dex991.htm",[64],[328],{"type":27,"value":329},"公布",{"type":27,"value":331},"，在一项纳入 183 名膝骨关节炎患者的试验里，UBX0101 的效果并不比安慰剂好。",{"type":22,"tag":23,"props":333,"children":334},{},[335,337,344,346,353],{"type":27,"value":336},"还有别的团队在小鼠身上让免疫系统去对付衰老细胞。他们用的是经过改造的免疫细胞（",{"type":22,"tag":60,"props":338,"children":341},{"href":339,"rel":340},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32555459\u002F",[64],[342],{"type":27,"value":343},"Amor 等，2020",{"type":27,"value":345},"），或者一种针对衰老相关蛋白 GPNMB 的疫苗（",{"type":22,"tag":60,"props":347,"children":350},{"href":348,"rel":349},"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs43587-021-00151-2",[64],[351],{"type":27,"value":352},"Suda 等，2021",{"type":27,"value":354},"）。这两篇论文都写明了针对的是哪种蛋白，Immorta 却没有交代。",{"type":22,"tag":23,"props":356,"children":357},{},[358,360,367,369,376,378,385],{"type":27,"value":359},"癌症让事情变得更复杂。细胞衰老本身就是身体防范肿瘤的一道防线。免疫系统可以清除这类细胞，",{"type":22,"tag":60,"props":361,"children":364},{"href":362,"rel":363},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F22080947\u002F",[64],[365],{"type":27,"value":366},"Kang 和同事",{"type":27,"value":368},"在癌前病变的肝细胞上就证明了这一点。可衰老细胞发出的信号也可能促进肿瘤生长（",{"type":22,"tag":60,"props":370,"children":373},{"href":371,"rel":372},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F11593017\u002F",[64],[374],{"type":27,"value":375},"Krtolica 等，2001",{"type":27,"value":377},"；",{"type":22,"tag":60,"props":379,"children":382},{"href":380,"rel":381},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F23140366\u002F",[64],[383],{"type":27,"value":384},"Campisi，2013",{"type":27,"value":386},"）。清除衰老细胞，并不等于治好癌症。",{"type":22,"tag":29,"props":388,"children":390},{"id":389},"九个氨基酸透露了什么",[391],{"type":27,"value":392},"“九个氨基酸”透露了什么",{"type":22,"tag":23,"props":394,"children":395},{},[396,398,405],{"type":27,"value":397},"几乎每个细胞的表面都带着一种“展示分子”（MHC I 类分子），它们把细胞内部的蛋白质短片段亮给免疫系统看。这些片段通常长 8 到 10 个氨基酸（",{"type":22,"tag":60,"props":399,"children":402},{"href":400,"rel":401},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F28367149\u002F",[64],[403],{"type":27,"value":404},"Wieczorek 等，2017",{"type":27,"value":406},"）。T 细胞会逐一检查，哪个细胞亮出的片段可疑，就攻击哪个细胞。",{"type":22,"tag":23,"props":408,"children":409},{},[410],{"type":27,"value":411},"所以，从目前披露的信息看，SenoMune-0257 很像一种经典的肽疫苗：把一个片段亮给免疫系统，让它照着去找。这就带来了两个问题。",{"type":22,"tag":23,"props":413,"children":414},{},[415,417,424,426,432],{"type":27,"value":416},"第一个问题是组织型。在人身上，这类展示分子叫 HLA，它的变体因人而异。一个九氨基酸的片段，通常只能与其中某些变体结合。Immorta 为自己的细胞疗法路线提交过一份",{"type":22,"tag":60,"props":418,"children":421},{"href":419,"rel":420},"https:\u002F\u002Fpatents.google.com\u002Fpatent\u002FWO2025226744A1\u002Fen",[64],[422],{"type":27,"value":423},"专利申请",{"type":27,"value":425},"，里面回顾了这类研究，例如一项用到“HLA-A",{"type":22,"tag":427,"props":428,"children":429},"em",{},[430],{"type":27,"value":431},"0201-restricted peptides”（HLA-A",{"type":27,"value":433},"0201 限制性肽）的研究。",{"type":22,"tag":23,"props":435,"children":436},{},[437],{"type":27,"value":438},"Immorta 没有公布 SenoMune-0257 结合的是哪一种 HLA 分子。",{"type":22,"tag":23,"props":440,"children":441},{},[442,444,451,453,460],{"type":27,"value":443},"拿最常见的变体之一 HLA-A*02:01 举个例子。根据",{"type":22,"tag":60,"props":445,"children":448},{"href":446,"rel":447},"https:\u002F\u002Fwww.allelefrequencies.net\u002Fhla\u002Fclassical-allele-frequency-search\u002F?allele=A*02:01",[64],[449],{"type":27,"value":450},"等位基因频率网络数据库（Allele Frequency Net Database）",{"type":27,"value":452},"（",{"type":22,"tag":60,"props":454,"children":457},{"href":455,"rel":456},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F31722398\u002F",[64],[458],{"type":27,"value":459},"Gonzalez-Galarza 等，2020",{"type":27,"value":461},"），在欧洲的大型登记库里，它约占全部基因拷贝的 28%。在非裔美国人中约为 12%，在美国骨髓登记库（NMDP）的华裔捐献者中约为 9%。",{"type":22,"tag":23,"props":463,"children":464},{},[465],{"type":27,"value":466},"每个人的每个 HLA 基因都有两份拷贝，一份来自父亲，一份来自母亲。粗略估算下来，欧洲裔中大约一半人至少带有一份（48%）。在非裔美国人中，这个比例约为四分之一（23%）；在华裔捐献者中约为五分之一（18%）。",{"type":22,"tag":23,"props":468,"children":469},{},[470],{"type":27,"value":471},"就算 SenoMune-0257 恰好匹配这个变体，欧洲人里仍有大约一半并不携带它，这和“universal”（通用）的说法很难对上。一种肽有时能匹配几个相近的变体，覆盖更多的人，但序列不公开，这一点就无从判断。",{"type":22,"tag":23,"props":473,"children":474},{},[475,477,484],{"type":27,"value":476},"第二个问题是，针对癌症的肽疫苗迄今表现如何。2004 年，",{"type":22,"tag":60,"props":478,"children":481},{"href":479,"rel":480},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F15340416\u002F",[64],[482],{"type":27,"value":483},"Rosenberg、Yang 和 Restifo",{"type":27,"value":485}," 回顾了他们自己在 440 名患者身上做过的癌症疫苗试验：“the objective response rate was low (2.6%)”（客观缓解率很低，只有 2.6%）。也就是说，每一百名患者里，肿瘤能测出缩小的还不到三人。",{"type":22,"tag":23,"props":487,"children":488},{},[489,491,498],{"type":27,"value":490},"Immorta 自己在一篇 ",{"type":22,"tag":60,"props":492,"children":495},{"href":493,"rel":494},"https:\u002F\u002Fdoi.org\u002F10.15406\u002Fjsrt.2024.09.00169",[64],[496],{"type":27,"value":497},"2024 年的综述",{"type":27,"value":499},"里也谈到过相关的问题：“single-antigen approaches leave open the possibility of immune editing and immune escape”（单一抗原的策略，给免疫编辑和免疫逃逸留下了余地）。说得直白些，如果疫苗只教免疫系统认一个目标，那些不再亮出这个目标的细胞就能溜掉。SenoMune-0257 恰恰就是这样一种单一的肽。",{"type":22,"tag":29,"props":501,"children":503},{"id":502},"目前都发表了哪些研究",[504],{"type":27,"value":502},{"type":22,"tag":23,"props":506,"children":507},{},[508],{"type":27,"value":509},"关于 SenoMune-0257，我们没有找到任何论文、预印本或专利。用这个名字检索文献，只搜到一种毫不相干的化妆品原料，名字恰好也叫 Senomune（一种绿茶根提取物）。专利申请一般在递交约 18 个月后才会公开，所以如果是最近才递交的，现在可能还看不到。Immorta 发表过的所有内容，讲的都是它更早的产品 SenoVax。",{"type":22,"tag":23,"props":511,"children":512},{},[513,520,522,527],{"type":22,"tag":60,"props":514,"children":517},{"href":515,"rel":516},"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12967-025-07393-3",[64],[518],{"type":27,"value":519},"第一篇 SenoVax 论文",{"type":27,"value":521},"于 2025 年 11 月发表在 ",{"type":22,"tag":427,"props":523,"children":524},{},[525],{"type":27,"value":526},"Journal of Translational Medicine",{"type":27,"value":528},"（《转化医学杂志》）上，那时的 SenoVax 是一种细胞产品，而不是肽。研究者先在实验室里用化疗药多柔比星（doxorubicin）让一批细胞衰老，再把从这些细胞中提取的物质装载到免疫细胞上。",{"type":22,"tag":23,"props":530,"children":531},{},[532],{"type":27,"value":533},"实验小鼠身上移植了肺癌、脑肿瘤、胰腺癌或乳腺癌，每组 10 只。肿瘤长得更慢了，而且这种保护作用可以通过一类 T 细胞（CD8+）传递。文中没有给出百分比，也没有生存数据。组织里的衰老细胞数量并没有测量，作者把这件事留给了“future studies”（今后的研究）。",{"type":22,"tag":23,"props":535,"children":536},{},[537,544],{"type":22,"tag":60,"props":538,"children":541},{"href":539,"rel":540},"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12967-026-08221-y",[64],[542],{"type":27,"value":543},"第二篇论文",{"type":27,"value":545},"发表于 2026 年 6 月，它把 SenoVax 描述为一种疫苗制剂，“comprising adjuvanted peptides derived from senescence-associated proteins”（由衰老相关蛋白衍生、并添加了佐剂的肽组成）。名字一样，两篇论文说的却是两种不同的产品。",{"type":22,"tag":23,"props":547,"children":548},{},[549],{"type":27,"value":550},"这一次用了两种模型：一种用化学药物（CCl₄）诱导肝损伤，另一种注射多柔比星，模拟加速衰老。多柔比星模型分五组，每组 10 只：一组只打生理盐水，一组只打多柔比星，其余三组在多柔比星之外分别加用 SenoVax、Immorta 的干细胞产品，或者两者同用。",{"type":22,"tag":23,"props":552,"children":553},{},[554],{"type":27,"value":555},"在肝损伤模型里，联合用药让血液中的两种肝酶（AST 和 ALT）下降了 58% 到 62%。单独使用其中任何一种，降幅为 32% 到 40%。",{"type":22,"tag":23,"props":557,"children":558},{},[559],{"type":27,"value":560},"“寿命”这项结果需要仔细读。根据一张图的说明，小鼠接受的多柔比星是“5 mg\u002Fkg three times per week … until death”（每公斤体重 5 毫克，每周三次……直到死亡）。所以测的是持续化疗下的存活时间，而不是自然寿命。单用多柔比星的小鼠，到第 30 天已全部死亡。联合用药组到第 35 天还有 50% 活着，到第 40 天还有 20%。",{"type":22,"tag":23,"props":562,"children":563},{},[564,566,573],{"type":27,"value":565},"有两封致编辑的信对这项研究提出了质疑。",{"type":22,"tag":60,"props":567,"children":570},{"href":568,"rel":569},"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12967-026-09014-z",[64],[571],{"type":27,"value":572},"Chen 和 Sun",{"type":27,"value":574}," 在 2026 年 10 月写道：“survival during ongoing doxorubicin exposure should not be described as lifespan extension”（在持续接受多柔比星期间的存活，不应被说成寿命延长）。他们还指出，方法部分写的是每周一次、每公斤 2 毫克，图里标的却是每周三次、每公斤 5 毫克。",{"type":22,"tag":23,"props":576,"children":577},{},[578,580,587],{"type":27,"value":579},"第二封信出自 ",{"type":22,"tag":60,"props":581,"children":584},{"href":582,"rel":583},"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12967-026-07820-z",[64],[585],{"type":27,"value":586},"Xie 和同事",{"type":27,"value":588},"，针对的是第一篇论文。信的语气很友好，但追问了长期安全性：“The immune damage of physiological sites (e.g. sites of tissue repair) was not investigated.”（对生理部位，例如组织修复部位造成的免疫损伤，并未加以研究。）",{"type":22,"tag":23,"props":590,"children":591},{},[592],{"type":27,"value":593},"第二篇论文还报告了效应量（Cohen's d），这是衡量两组差别有多大的一个指标。按惯例，0.8 就已经算大了。而这里的平均效应量最高达到 27，单个数值最高达到 55。差别大到这种程度，需要由其他团队独立重复验证。",{"type":22,"tag":23,"props":595,"children":596},{},[597],{"type":27,"value":598},"两篇论文都声明，论文的发表“was funded by Immorta Bio Inc.”（由 Immorta Bio Inc. 资助）。论文列出的三位作者（包括 Ichim）是公司的管理层成员和股东。这些都做了规范的披露，同时也意味着，所有已发表的 SenoVax 数据都出自公司自己。",{"type":22,"tag":29,"props":600,"children":602},{"id":601},"宣布了多少兑现了多少",[603],{"type":27,"value":604},"宣布了多少，兑现了多少",{"type":22,"tag":23,"props":606,"children":607},{},[608],{"type":27,"value":609},"从 2024 年起，Immorta 一次又一次宣布要朝人体试验迈进。",{"type":22,"tag":141,"props":611,"children":612},{},[613,629],{"type":22,"tag":145,"props":614,"children":615},{},[616],{"type":22,"tag":149,"props":617,"children":618},{},[619,624],{"type":22,"tag":153,"props":620,"children":621},{},[622],{"type":27,"value":623},"日期",{"type":22,"tag":153,"props":625,"children":626},{},[627],{"type":27,"value":628},"公司当时的说法",{"type":22,"tag":164,"props":630,"children":631},{},[632,650,668,686,704,722,740,758,775],{"type":22,"tag":149,"props":633,"children":634},{},[635,645],{"type":22,"tag":171,"props":636,"children":637},{},[638],{"type":22,"tag":60,"props":639,"children":642},{"href":640,"rel":641},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-files-investigational-new-drug-application-for-first-in-class-senolytic-immunotherapy-senovax-for-treatment-of-advanced-lung-cancer-302207491.html",[64],[643],{"type":27,"value":644},"2024 年 7 月",{"type":22,"tag":171,"props":646,"children":647},{},[648],{"type":27,"value":649},"为 SenoVax 治疗晚期肺癌递交了开展人体试验的申请（IND），档案编号 30745。当时的 SenoVax 是一种用患者自身细胞制成的细胞产品。",{"type":22,"tag":149,"props":651,"children":652},{},[653,663],{"type":22,"tag":171,"props":654,"children":655},{},[656],{"type":22,"tag":60,"props":657,"children":660},{"href":658,"rel":659},"https:\u002F\u002Fwww.immortabio.com\u002Fnews\u002Fdiseases-aging-thomas-ichim",[64],[661],{"type":27,"value":662},"2024 年 10 月",{"type":22,"tag":171,"props":664,"children":665},{},[666],{"type":27,"value":667},"目标是“complete the Phase I\u002FIIa trial by Q3 2025”（在 2025 年第三季度前完成 I\u002FIIa 期试验）。",{"type":22,"tag":149,"props":669,"children":670},{},[671,681],{"type":22,"tag":171,"props":672,"children":673},{},[674],{"type":22,"tag":60,"props":675,"children":678},{"href":676,"rel":677},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-reports-preclinical-activity-of-senolytic-immunotherapy-senovax-in-a-chronic-traumatic-encephalopathy-cte-model-302565883.html",[64],[679],{"type":27,"value":680},"2025 年 9 月",{"type":22,"tag":171,"props":682,"children":683},{},[684],{"type":27,"value":685},"一次生产批次是“the remaining step prior to IND clearance”（IND 获准之前剩下的最后一步）。",{"type":22,"tag":149,"props":687,"children":688},{},[689,699],{"type":22,"tag":171,"props":690,"children":691},{},[692],{"type":22,"tag":60,"props":693,"children":696},{"href":694,"rel":695},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-reports-reduction-of-tumors-in-validated-models-of-lung-brain-pancreatic-and-breast-cancers-using-anti-aging-vaccine-senovax-302633350.html",[64],[697],{"type":27,"value":698},"2025 年 12 月",{"type":22,"tag":171,"props":700,"children":701},{},[702],{"type":27,"value":703},"“completing the required GMP manufacturing run to enable initiation”（正在完成启动试验所必需的 GMP 生产批次）。",{"type":22,"tag":149,"props":705,"children":706},{},[707,717],{"type":22,"tag":171,"props":708,"children":709},{},[710],{"type":22,"tag":60,"props":711,"children":714},{"href":712,"rel":713},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-doubles-mouse-lifespan-using-combination-senolytic-and-regenerative-therapy-in-validated-aging-models-302656482.html",[64],[715],{"type":27,"value":716},"2026 年 1 月",{"type":22,"tag":171,"props":718,"children":719},{},[720],{"type":27,"value":721},"“Doubles Mouse Lifespan”（小鼠寿命翻倍）；SenoVax“currently under FDA review”（目前正在接受 FDA 审查）。",{"type":22,"tag":149,"props":723,"children":724},{},[725,735],{"type":22,"tag":171,"props":726,"children":727},{},[728],{"type":22,"tag":60,"props":729,"children":732},{"href":730,"rel":731},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-demonstrates-dramatic-lifespan-extension-in-aging-mouse-models-research-accepted-for-presentation-at-aais-immunology2026-302711019.html",[64],[733],{"type":27,"value":734},"2026 年 3 月",{"type":22,"tag":171,"props":736,"children":737},{},[738],{"type":27,"value":739},"衰老小鼠模型：“~73% increase in mean survival and ~84% extension of median lifespan”（平均生存期延长约 73%，中位寿命延长约 84%）。",{"type":22,"tag":149,"props":741,"children":742},{},[743,753],{"type":22,"tag":171,"props":744,"children":745},{},[746],{"type":22,"tag":60,"props":747,"children":750},{"href":748,"rel":749},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-publishes-over-70-increased-longevity-in-aging-animals-by-its-patented-therapeutic-combination-302798055.html",[64],[751],{"type":27,"value":752},"2026 年 6 月",{"type":22,"tag":171,"props":754,"children":755},{},[756],{"type":27,"value":757},"第二篇论文发表之际：“over 70% lifespan extension”（寿命延长超过 70%）。",{"type":22,"tag":149,"props":759,"children":760},{},[761,770],{"type":22,"tag":171,"props":762,"children":763},{},[764],{"type":22,"tag":60,"props":765,"children":767},{"href":112,"rel":766},[64],[768],{"type":27,"value":769},"2026 年 10 月",{"type":22,"tag":171,"props":771,"children":772},{},[773],{"type":27,"value":774},"SenoMune-0257：临床前研究完成，“initial human evaluation anticipated before year-end”（预计年底前进行首次人体评估）。",{"type":22,"tag":149,"props":776,"children":777},{},[778,788],{"type":22,"tag":171,"props":779,"children":780},{},[781],{"type":22,"tag":60,"props":782,"children":785},{"href":783,"rel":784},"https:\u002F\u002Fclinicaltrials.gov\u002Fapi\u002Fv2\u002Fstudies?query.term=SenoVax",[64],[786],{"type":27,"value":787},"2026 年 10 月 26 日",{"type":22,"tag":171,"props":789,"children":790},{},[791],{"type":27,"value":792},"在 ClinicalTrials.gov 上检索 SenoVax、SenoMune 或 Immorta，结果都是 0 项研究。",{"type":22,"tag":23,"props":794,"children":795},{},[796],{"type":27,"value":797},"在加速衰老模型上，公司给出的数字先是“doubled”（翻倍），然后是 73% 和 84%，后来又成了“over 70%”（超过 70%）。论文本身并没有给出寿命延长的百分比。",{"type":22,"tag":23,"props":799,"children":800},{},[801],{"type":27,"value":802},"IND 编号 30745 是 FDA 给一份申请分配的档案号，并不代表获批。2026 年 1 月，公司称这份申请正在接受 FDA 审查；此后有没有获准，外界无从得知。",{"type":22,"tag":23,"props":804,"children":805},{},[806,808,815],{"type":27,"value":807},"Immorta 向美国证券交易委员会提交的文件（",{"type":22,"tag":60,"props":809,"children":812},{"href":810,"rel":811},"https:\u002F\u002Fwww.sec.gov\u002FArchives\u002Fedgar\u002Fdata\u002F2102665\u002F000210266526000002\u002FxslFormDX01\u002Fprimary_doc.xml",[64],[813],{"type":27,"value":814},"Form D",{"type":27,"value":816},"）显示，这是一家没有营收的私营公司，2023 年在特拉华州注册成立。从 2024 年 11 月起，它一直在通过私募向投资者筹资。",{"type":22,"tag":23,"props":818,"children":819},{},[820],{"type":27,"value":821},"最新一份文件（2026 年 10 月 16 日）显示，公司已从六名投资者那里募得 612,503 美元，募资上限为 500 万美元。更早的一份（2026 年 1 月 8 日）报告的是已募得 45 万美元，上限为 50 万美元。",{"type":22,"tag":29,"props":823,"children":825},{"id":824},"能买到-senomune-0257-吗",[826],{"type":27,"value":827},"能买到 SenoMune-0257 吗？",{"type":22,"tag":23,"props":829,"children":830},{},[831,833,840],{"type":27,"value":832},"买不到。它的序列从未公布，所以任何打着这个名字卖东西的人，都不可能知道自己做出来的是什么。2026 年 10 月 26 日我们在网上搜了一遍，没有发现哪家店在卖它，不过这次搜索没有覆盖各种聊天群和即时通讯渠道。有一种用绿茶根制成的",{"type":22,"tag":60,"props":834,"children":837},{"href":835,"rel":836},"https:\u002F\u002Fdoi.org\u002F10.1111\u002Fexd.70366",[64],[838],{"type":27,"value":839},"化妆品原料",{"type":27,"value":841},"也叫这个名字，但和它毫无关系。",{"type":22,"tag":23,"props":843,"children":844},{},[845,847,854,856,862],{"type":27,"value":846},"在相关讨论里，你可能还见过 FOXO4-DRI，这是一种专门设计来诱导衰老细胞死亡的肽。在 ",{"type":22,"tag":60,"props":848,"children":851},{"href":849,"rel":850},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F28340339\u002F",[64],[852],{"type":27,"value":853},"Baar 和同事",{"type":27,"value":855}," 2017 年的一项研究里，它让老年小鼠的体能、毛发和肾功能都有所改善。它从来没有做过人体研究。我们的 ",{"type":22,"tag":60,"props":857,"children":859},{"href":858},"\u002Fpeptides\u002Ffoxo4-dri",[860],{"type":27,"value":861},"FOXO4-DRI 专题页",{"type":27,"value":863},"梳理了目前已知和未知的内容。",{"type":22,"tag":29,"props":865,"children":867},{"id":866},"如何自己核查重大突破类帖子",[868],{"type":27,"value":869},"如何自己核查“重大突破”类帖子",{"type":22,"tag":871,"props":872,"children":873},"ul",{},[874,880,885,890,904,909],{"type":22,"tag":875,"props":876,"children":877},"li",{},[878],{"type":27,"value":879},"找到一手来源，比如新闻稿或研究原文，看看里面到底写了什么。",{"type":22,"tag":875,"props":881,"children":882},{},[883],{"type":27,"value":884},"查一查有没有经过同行评审的论文，还是只有一份由公司自己撰写的新闻稿。",{"type":22,"tag":875,"props":886,"children":887},{},[888],{"type":27,"value":889},"弄清楚结果来自人、来自动物，还是来自培养皿里的细胞。",{"type":22,"tag":875,"props":891,"children":892},{},[893,895,902],{"type":27,"value":894},"到 ",{"type":22,"tag":60,"props":896,"children":899},{"href":897,"rel":898},"https:\u002F\u002Fclinicaltrials.gov\u002F",[64],[900],{"type":27,"value":901},"ClinicalTrials.gov",{"type":27,"value":903}," 上搜一搜药名和公司名，人体试验通常都会在那里登记。",{"type":22,"tag":875,"props":905,"children":906},{},[907],{"type":27,"value":908},"读一读经费来源和利益冲突声明，看看这项研究是谁出的钱。",{"type":22,"tag":875,"props":910,"children":911},{},[912],{"type":27,"value":913},"留意是谁在传播这条消息，以及他们自己是不是在卖相关的东西。",{"type":22,"tag":29,"props":915,"children":917},{"id":916},"总结",[918],{"type":27,"value":916},{"type":22,"tag":23,"props":920,"children":921},{},[922],{"type":27,"value":923},"SenoMune-0257 眼下只是一则公告，还谈不上任何结果。现有的，是一份没有数据的新闻稿，再加上公司科学家的一条帖子，把它称作癌症免疫疗法。随后，一个挂着卖货链接的账号又把它说成了能治愈癌症。这种肽没有在人身上试过，也没有登记任何试验。",{"type":22,"tag":23,"props":925,"children":926},{},[927],{"type":27,"value":928},"训练免疫系统去清除衰老细胞，是一个严肃的研究方向：在小鼠身上有实实在在的结果，在人身上则成败参半。这种肽到底有没有用，要等数据发表、登记过的试验报告结果之后才能知道。在那之前，它买不到，也不存在什么用量。",{"type":22,"tag":23,"props":930,"children":931},{},[932,934,940,942,948],{"type":27,"value":933},"如果你想先补一补基础，可以从",{"type":22,"tag":60,"props":935,"children":937},{"href":936},"\u002Fwhat-are-peptides",[938],{"type":27,"value":939},"什么是肽",{"type":27,"value":941},"看起。如果本文提到了你，而你认为其中某项事实陈述有误，请通过我们的",{"type":22,"tag":60,"props":943,"children":945},{"href":944},"\u002Flegal-notice",[946],{"type":27,"value":947},"法律声明",{"type":27,"value":949},"页面与我们联系。",{"type":22,"tag":29,"props":951,"children":953},{"id":952},"参考来源",[954],{"type":27,"value":952},{"type":22,"tag":871,"props":956,"children":957},{},[958,969,979,990,1001,1012,1023,1034,1045,1056,1067,1078,1089,1100,1111,1122,1133,1144,1155,1166,1177,1188,1199,1210,1221,1232,1243,1254,1265,1276,1287,1298,1309,1320,1331,1342],{"type":22,"tag":875,"props":959,"children":960},{},[961,963],{"type":27,"value":962},"@ItsPeptime（X），2026 年 10 月 24 日，",{"type":22,"tag":60,"props":964,"children":966},{"href":62,"rel":965},[64],[967],{"type":27,"value":968},"Post on SenoMune-0257",{"type":22,"tag":875,"props":970,"children":971},{},[972,974],{"type":27,"value":973},"Thomas Ichim（@exosome，X），2026 年 10 月 23 日，",{"type":22,"tag":60,"props":975,"children":977},{"href":87,"rel":976},[64],[978],{"type":27,"value":968},{"type":22,"tag":875,"props":980,"children":981},{},[982,984],{"type":27,"value":983},"Immorta Bio，2026 年 10 月 12 日，",{"type":22,"tag":60,"props":985,"children":987},{"href":112,"rel":986},[64],[988],{"type":27,"value":989},"Immorta Bio Pioneers AI-Designed Senolytic Immunotherapy Targeting Diseases of Aging",{"type":22,"tag":875,"props":991,"children":992},{},[993,995],{"type":27,"value":994},"Immorta Bio，2024 年 7 月 26 日，",{"type":22,"tag":60,"props":996,"children":998},{"href":640,"rel":997},[64],[999],{"type":27,"value":1000},"Immorta Bio Files IND for SenoVax for Advanced Lung Cancer",{"type":22,"tag":875,"props":1002,"children":1003},{},[1004,1006],{"type":27,"value":1005},"Immorta Bio，2024 年 10 月 2 日，",{"type":22,"tag":60,"props":1007,"children":1009},{"href":658,"rel":1008},[64],[1010],{"type":27,"value":1011},"Diseases of Aging: Q&A with Dr. Thomas Ichim",{"type":22,"tag":875,"props":1013,"children":1014},{},[1015,1017],{"type":27,"value":1016},"Immorta Bio，2025 年 9 月 24 日，",{"type":22,"tag":60,"props":1018,"children":1020},{"href":676,"rel":1019},[64],[1021],{"type":27,"value":1022},"Preclinical Activity of SenoVax in a CTE Model",{"type":22,"tag":875,"props":1024,"children":1025},{},[1026,1028],{"type":27,"value":1027},"Immorta Bio，2025 年 12 月 4 日，",{"type":22,"tag":60,"props":1029,"children":1031},{"href":694,"rel":1030},[64],[1032],{"type":27,"value":1033},"Reduction of Tumors Using SenoVax",{"type":22,"tag":875,"props":1035,"children":1036},{},[1037,1039],{"type":27,"value":1038},"Immorta Bio，2026 年 1 月 8 日，",{"type":22,"tag":60,"props":1040,"children":1042},{"href":712,"rel":1041},[64],[1043],{"type":27,"value":1044},"Immorta Bio Doubles Mouse Lifespan",{"type":22,"tag":875,"props":1046,"children":1047},{},[1048,1050],{"type":27,"value":1049},"Immorta Bio，2026 年 3 月 11 日，",{"type":22,"tag":60,"props":1051,"children":1053},{"href":730,"rel":1052},[64],[1054],{"type":27,"value":1055},"Dramatic Lifespan Extension in Aging Mouse Models",{"type":22,"tag":875,"props":1057,"children":1058},{},[1059,1061],{"type":27,"value":1060},"Immorta Bio，2026 年 6 月 11 日，",{"type":22,"tag":60,"props":1062,"children":1064},{"href":748,"rel":1063},[64],[1065],{"type":27,"value":1066},"Over 70% Increased Longevity in Aging Animals",{"type":22,"tag":875,"props":1068,"children":1069},{},[1070,1072],{"type":27,"value":1071},"U.S. Securities and Exchange Commission，2026 年 10 月 16 日，",{"type":22,"tag":60,"props":1073,"children":1075},{"href":810,"rel":1074},[64],[1076],{"type":27,"value":1077},"Form D, Immorta Bio, Inc. (CIK 0002102665)",{"type":22,"tag":875,"props":1079,"children":1080},{},[1081,1083],{"type":27,"value":1082},"ClinicalTrials.gov，2026 年 10 月 26 日，",{"type":22,"tag":60,"props":1084,"children":1086},{"href":783,"rel":1085},[64],[1087],{"type":27,"value":1088},"Search for SenoVax (SenoMune and Immorta likewise 0 results)",{"type":22,"tag":875,"props":1090,"children":1091},{},[1092,1094],{"type":27,"value":1093},"Immorta Bio，2025 年 10 月 30 日，",{"type":22,"tag":60,"props":1095,"children":1097},{"href":419,"rel":1096},[64],[1098],{"type":27,"value":1099},"WO2025226744A1: Senescent cell targeting T cell responses",{"type":22,"tag":875,"props":1101,"children":1102},{},[1103,1105],{"type":27,"value":1104},"Ichim 等，Journal of Translational Medicine 2025，",{"type":22,"tag":60,"props":1106,"children":1108},{"href":515,"rel":1107},[64],[1109],{"type":27,"value":1110},"Reduction of solid tumors by senescent cell immunization",{"type":22,"tag":875,"props":1112,"children":1113},{},[1114,1116],{"type":27,"value":1115},"Ichim 等，Journal of Translational Medicine 2026，",{"type":22,"tag":60,"props":1117,"children":1119},{"href":539,"rel":1118},[64],[1120],{"type":27,"value":1121},"Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan",{"type":22,"tag":875,"props":1123,"children":1124},{},[1125,1127],{"type":27,"value":1126},"Chen 和 Sun，Journal of Translational Medicine 2026，",{"type":22,"tag":60,"props":1128,"children":1130},{"href":568,"rel":1129},[64],[1131],{"type":27,"value":1132},"Treatment benefit does not establish senolysis or lifespan extension",{"type":22,"tag":875,"props":1134,"children":1135},{},[1136,1138],{"type":27,"value":1137},"Xie 等，Journal of Translational Medicine 2026，",{"type":22,"tag":60,"props":1139,"children":1141},{"href":582,"rel":1140},[64],[1142],{"type":27,"value":1143},"Letter to the editor: clinical translation of senolytic immunotherapy: critical considerations for SenoVax and beyond",{"type":22,"tag":875,"props":1145,"children":1146},{},[1147,1149],{"type":27,"value":1148},"Veklych 等，Journal of Stem Cell Research & Therapeutics 2024，",{"type":22,"tag":60,"props":1150,"children":1152},{"href":493,"rel":1151},[64],[1153],{"type":27,"value":1154},"Can senolysis be used to overcome tumor immune evasion?",{"type":22,"tag":875,"props":1156,"children":1157},{},[1158,1160],{"type":27,"value":1159},"Hayflick 和 Moorhead，Experimental Cell Research 1961，",{"type":22,"tag":60,"props":1161,"children":1163},{"href":256,"rel":1162},[64],[1164],{"type":27,"value":1165},"The serial cultivation of human diploid cell strains",{"type":22,"tag":875,"props":1167,"children":1168},{},[1169,1171],{"type":27,"value":1170},"Coppé 等，PLoS Biology 2008，",{"type":22,"tag":60,"props":1172,"children":1174},{"href":265,"rel":1173},[64],[1175],{"type":27,"value":1176},"Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor",{"type":22,"tag":875,"props":1178,"children":1179},{},[1180,1182],{"type":27,"value":1181},"Baker 等，Nature 2011，",{"type":22,"tag":60,"props":1183,"children":1185},{"href":279,"rel":1184},[64],[1186],{"type":27,"value":1187},"Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders",{"type":22,"tag":875,"props":1189,"children":1190},{},[1191,1193],{"type":27,"value":1192},"Baker 等，Nature 2016，",{"type":22,"tag":60,"props":1194,"children":1196},{"href":288,"rel":1195},[64],[1197],{"type":27,"value":1198},"Naturally occurring p16Ink4a-positive cells shorten healthy lifespan",{"type":22,"tag":875,"props":1200,"children":1201},{},[1202,1204],{"type":27,"value":1203},"Xu 等，Nature Medicine 2018，",{"type":22,"tag":60,"props":1205,"children":1207},{"href":302,"rel":1206},[64],[1208],{"type":27,"value":1209},"Senolytics improve physical function and increase lifespan in old age",{"type":22,"tag":875,"props":1211,"children":1212},{},[1213,1215],{"type":27,"value":1214},"Justice 等，EBioMedicine 2019，",{"type":22,"tag":60,"props":1216,"children":1218},{"href":316,"rel":1217},[64],[1219],{"type":27,"value":1220},"Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study",{"type":22,"tag":875,"props":1222,"children":1223},{},[1224,1226],{"type":27,"value":1225},"UNITY Biotechnology，2020 年 8 月 17 日，",{"type":22,"tag":60,"props":1227,"children":1229},{"href":325,"rel":1228},[64],[1230],{"type":27,"value":1231},"UBX0101 phase 2 12-week data (Form 8-K, Exhibit 99.1)",{"type":22,"tag":875,"props":1233,"children":1234},{},[1235,1237],{"type":27,"value":1236},"Amor 等，Nature 2020，",{"type":22,"tag":60,"props":1238,"children":1240},{"href":339,"rel":1239},[64],[1241],{"type":27,"value":1242},"Senolytic CAR T cells reverse senescence-associated pathologies",{"type":22,"tag":875,"props":1244,"children":1245},{},[1246,1248],{"type":27,"value":1247},"Suda 等，Nature Aging 2021，",{"type":22,"tag":60,"props":1249,"children":1251},{"href":348,"rel":1250},[64],[1252],{"type":27,"value":1253},"Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice",{"type":22,"tag":875,"props":1255,"children":1256},{},[1257,1259],{"type":27,"value":1258},"Kang 等，Nature 2011，",{"type":22,"tag":60,"props":1260,"children":1262},{"href":362,"rel":1261},[64],[1263],{"type":27,"value":1264},"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development",{"type":22,"tag":875,"props":1266,"children":1267},{},[1268,1270],{"type":27,"value":1269},"Krtolica 等，PNAS 2001，",{"type":22,"tag":60,"props":1271,"children":1273},{"href":371,"rel":1272},[64],[1274],{"type":27,"value":1275},"Senescent fibroblasts promote epithelial cell growth and tumorigenesis",{"type":22,"tag":875,"props":1277,"children":1278},{},[1279,1281],{"type":27,"value":1280},"Campisi，Annual Review of Physiology 2013，",{"type":22,"tag":60,"props":1282,"children":1284},{"href":380,"rel":1283},[64],[1285],{"type":27,"value":1286},"Aging, cellular senescence, and cancer",{"type":22,"tag":875,"props":1288,"children":1289},{},[1290,1292],{"type":27,"value":1291},"Wieczorek 等，Frontiers in Immunology 2017，",{"type":22,"tag":60,"props":1293,"children":1295},{"href":400,"rel":1294},[64],[1296],{"type":27,"value":1297},"MHC class I and MHC class II proteins: conformational plasticity in antigen presentation",{"type":22,"tag":875,"props":1299,"children":1300},{},[1301,1303],{"type":27,"value":1302},"Allele Frequency Net Database，2026 年 10 月 26 日，",{"type":22,"tag":60,"props":1304,"children":1306},{"href":446,"rel":1305},[64],[1307],{"type":27,"value":1308},"Allele report HLA-A*02:01",{"type":22,"tag":875,"props":1310,"children":1311},{},[1312,1314],{"type":27,"value":1313},"Gonzalez-Galarza 等，Nucleic Acids Research 2020，",{"type":22,"tag":60,"props":1315,"children":1317},{"href":455,"rel":1316},[64],[1318],{"type":27,"value":1319},"Allele frequency net database (AFND) 2020 update",{"type":22,"tag":875,"props":1321,"children":1322},{},[1323,1325],{"type":27,"value":1324},"Rosenberg 等，Nature Medicine 2004，",{"type":22,"tag":60,"props":1326,"children":1328},{"href":479,"rel":1327},[64],[1329],{"type":27,"value":1330},"Cancer immunotherapy: moving beyond current vaccines",{"type":22,"tag":875,"props":1332,"children":1333},{},[1334,1336],{"type":27,"value":1335},"Park 等，Experimental Dermatology 2026，",{"type":22,"tag":60,"props":1337,"children":1339},{"href":835,"rel":1338},[64],[1340],{"type":27,"value":1341},"Plant-derived senolytic ingredient, Camellia sinensis root extract",{"type":22,"tag":875,"props":1343,"children":1344},{},[1345,1347],{"type":27,"value":1346},"Baar 等，Cell 2017，",{"type":22,"tag":60,"props":1348,"children":1350},{"href":849,"rel":1349},[64],[1351],{"type":27,"value":1352},"Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging",{"title":7,"searchDepth":1354,"depth":1354,"links":1355},2,[1356,1357,1358,1359,1360,1361,1362,1363,1364,1365,1366,1367],{"id":31,"depth":1354,"text":31},{"id":51,"depth":1354,"text":51},{"id":101,"depth":1354,"text":104},{"id":136,"depth":1354,"text":139},{"id":245,"depth":1354,"text":248},{"id":389,"depth":1354,"text":392},{"id":502,"depth":1354,"text":502},{"id":601,"depth":1354,"text":604},{"id":824,"depth":1354,"text":827},{"id":866,"depth":1354,"text":869},{"id":916,"depth":1354,"text":916},{"id":952,"depth":1354,"text":952},"markdown","content:blog:zh:senomune-0257-fact-check.md","content","blog\u002Fzh\u002Fsenomune-0257-fact-check.md","blog\u002Fzh\u002Fsenomune-0257-fact-check","md"]